DBV Technologies S.A. Securities Litigation

If you purchased a significant amount of shares of DBV Technologies S.A. (NASDAQ: DBVT), you have certain options. Investors should register for updates.


Lawsuit Overview

Defendant:DBV Technologies S.A.
Date Filed:January 15th, 2019
Sector:Health Care
Industry:Biotechnology: Biological Products (No Diagnostic Substances)

According to the Complaint, DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate was Viaskin Peanut, an immunotherapy product, which completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.

The Complaint alleges that during the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) DBV Technologies' Biologics License Application ("BLA") for Viaskin Peanut failed to provide the FDA with sufficient data on manufacturing procedures and quality controls; (2) consequently, DBV Technologies voluntarily withdrew the BLA for Viaskin Peanut; and (3) as a result, Defendants' statements about DBV Technologies' business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for DBV Technologies S.A.

First Identified Complaint

Travis Ito-Stone, et al. v. DBV Technologies S.A., et al.

Date Filed:January 15th, 2019
Class Period Start:February 14th, 2018
Class Period End:December 19th, 2018
First Identified Complaint Filings
#Document TitleFiling Date